First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Published:2018-12-06 Issue:23 Volume:379 Page:2220-2229
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Horn Leora¹,Mansfield Aaron S.¹,Szczęsna Aleksandra¹,Havel Libor¹,Krzakowski Maciej¹,Hochmair Maximilian J.¹,Huemer Florian¹,Losonczy György¹,Johnson Melissa L.¹,Nishio Makoto¹,Reck Martin¹,Mok Tony¹,Lam Sivuonthanh¹,Shames David S.¹,Liu Juan¹,Ding Beiying¹,Lopez-Chavez Ariel¹,Kabbinavar Fairooz¹,Lin Wei¹,Sandler Alan¹,Liu Stephen V.¹

Affiliation:

1. From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute–Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) — both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the...

Funder

F. Hoffmann-La Roche / Genentech

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1809064

Cited by 2415 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomes-enabled cancer chemoimmunotherapy;Biomaterials;2025-02

2. A multi-adjuvant nanovaccine platform based on targeted delivery of specific antigens for cancer immunotherapy;Nano Today;2024-12

3. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy;International Immunopharmacology;2024-11

4. Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer;Respiratory Medicine and Research;2024-11

5. Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer;Respiratory Medicine and Research;2024-11